Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@jax.org
Therapy Name | LM-24C5 |
Synonyms | |
Therapy Description |
LM-24C5 is a bispecific antibody that targets both CEACAM5 and TNFRSF9 (4-1BB), leading to increased TNFRSF9 (4-1BB) signaling and T-cell activation, and potentially resulting in decreased growth of CEACAM5-expressing tumors (Cancer Res (2023) 83 (7_Supplement): 2650). |
Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
---|---|---|---|---|
LM-24C5 | LM24C5 | CEACAM5 Antibody 7 TNFRSF9 Antibody 30 | LM-24C5 is a bispecific antibody that targets both CEACAM5 and TNFRSF9 (4-1BB), leading to increased TNFRSF9 (4-1BB) signaling and T-cell activation, and potentially resulting in decreased growth of CEACAM5-expressing tumors (Cancer Res (2023) 83 (7_Supplement): 2650). |
Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
---|
Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
---|---|---|---|---|---|---|
NCT06187402 | Phase Ib/II | LM-24C5 | A Study of LM-24C5 For Advanced Solid Tumors | Recruiting | USA | 0 |